SUVmax and TBR were significantly higher with <sup>68</sup>Ga-PSMA-11 (17.02 (9.40-27.07) vs 4.17 (3.55-5.17), P = 0.005, r = 0.80; 26.88 (14.85-42.77) vs 3.96 (3.38-4.93), P = 0.002, r = 0.85).<h4>Conclusions</h4><sup>68</sup>Ga-PSMA-11 PET/CT shows higher tracer avidity and tumor-to-background contrast than <sup>18</sup>F-FDG PET/CT for detecting residual primary tumors, lymph node, and bone metastases after therapy in metastatic prostate cancer. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.